Portfolio case studies

What is your vision?

What is the problem you are trying to solve?

Our vision at Mosaic is to be the world leader in biomarker-specific, targeted oncology drug discovery, development and commercialisation.

We are addressing a huge unmet need for patients with cancer. The mean five-year survival rate across all cancer types is still only 51%. As academia, government, and private industry strive to improve patient outcomes, the clinical failure rate in oncology drug development sits at a dismal 93%. The opportunity and urgency to improve the lives of people with cancer is immense, and Mosaic is uniquely positioned to play a leading role in addressing this societal challenge.

CIC is a tremendous partner to Mosaic. Their position in the Cambridge biosciences ecosystem and years of experience in building world-class companies with global impact, has been instrumental in helping us shape our strategy and vision to become a world-leading oncology therapeutics company.

BRIAN GLADSDEN CEO

What is unique about your product/technology?

At Mosaic, we are resolving cancer’s complexity by reshaping the interface of computational and experimental biology to power new medicines for patients. Typically, cancer drug discovery and development has been hypothesis-driven, retrospective and biased. Past approaches are too time consuming and costly, and with over 800 known cancer fitness genes, over 200 cancer types, and over 2,000 known genetic biomarkers, identifying an effective medicine is like finding a needle in a haystack.

Our platform takes a large-scale, agnostic and prospective approach to identify and develop novel targeted therapies, completely reinventing the traditional approach to target and drug discovery. Our bespoke partnership with the Sanger Institute also provides us with expertise and access to biological matter that few other companies in the world have.